Clinical trials: Gastrointestinal Tumor
Pain, Cancer
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy.
- Conditions
- Pain, Cancer, Colonic Diseases
- Trial name
- NCT01926444
- Testing
- GIC-1001
- Where
- 15 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- gicare Pharma Inc.
Unresectable or Metastatic Colorectal Cancer
Study Of Sunitinib With FOLFIRI In Colorectal Cancer
To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients
- Trial name
- NCT00668863
- Testing
- FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil), Sunitinib
- Where
- 10 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer
A non-randomized phase II study to determine the efficacy and safety of the combination of Pemetrexed and Irinotecan every two weeks in metastatic colorectal cancer patients.
- Trial name
- NCT00191984
- Testing
- pemetrexed, irinotecan
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Liver Neoplasms
Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma
The purpose of the study is to determine whether seocalcitol is effective in the treatment of advanced primary liver cancer (hepatocellular carcinoma [HCC]).
- Trial name
- NCT00051532
- Testing
- Seocalcitol
- Where
- 5 sites in Canada, France and 3 more
- Volunteers
- 700 people
- Sponsor
- LEO Pharma
Hepatic Impairment, Healthy Participants
Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
The purpose of this study is to assess the drug levels and safety of BMS-986278 in participants with mild, moderate, and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
- Trial name
- NCT06425198
- Testing
- BMS-986278
- Where
- 4 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Metastatic Pancreatic Cancer
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose disease has not progressed on first line…
- Trial name
- NCT04300114
- Testing
- Fluzoparib
- Where
- 23 sites in China
- Volunteers
- 5 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Neoplasms, Colorectal
Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
The purpose of this study is to determine the highest, tolerated dose level and safety of lapatinib, capecitabine and oxaliplatin in subjects with advanced cancer and to determine the clinical activity of the combination of drugs…
- Trial name
- NCT00536809
- Testing
- lapatinib, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests.
- Trial name
- FACT (NCT02390947)
- Testing
- Famitinib
- Where
- 44 sites in China
- Volunteers
- 543 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Neoplasms, Colonic Neoplasms
Study Evaluating EKB-569 in Advanced Colorectal Cancer
This non-randomized, open-label, outpatient clinical trial is designed to assess the safety and efficacy of daily orally administered EKB-569 in subjects with advanced colorectal cancer.
- Conditions
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- NCT00072748
- Testing
- EKB-569
- Volunteers
- 63 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
NSCLC, Gastric Cancer
A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors
This is a Phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) participants with relapsed/refractory non-small cell lung cancer (NSCLC) and HA-high participants with…
- Trial name
- NCT02563548
- Testing
- PEGPH20, Pembrolizumab
- Where
- 28 sites in United States
- Volunteers
- 56 people
- Sponsor
- Halozyme Therapeutics
Gastric Cancer
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
- Trial name
- NCT04768686
- Testing
- FLX475, Pembrolizumab
- Where
- 10 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Gastrointestinal Cancer
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.
- Trial name
- NCT00089960
- Testing
- AMG 706
- Volunteers
- 138 people
- Sponsor
- Amgen
Gastrointestinal Stromal Tumors
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Gastrointestinal stromal tumors (GIST) compose approximately 20% of soft tissue sarcomas with an annual incidence of approximately 7 per million population.
- Trial name
- NCT04106024
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cttq
Colorectal Cancer
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic…
- Trial name
- NCT00012389
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- 154 sites in United States, Brazil and 5 more
- Sponsor
- Sanofi
Biliary Tract Cancer
Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
A study to assess the safety and efficacy of durvalumab in combination with gemcitabine-based chemotherapy regimens in participants with aBTC.
- Trial name
- TOURMALINE (NCT05771480)
- Testing
- Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin
- Where
- 34 sites in United States, France and 6 more
- Volunteers
- 142 people
- Sponsor
- AstraZeneca
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.